ArticleHealth economics review2013

Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain.

Carlos Crespo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.